The pro-atherogenic enzyme PAPP-A is active in eluates from human carotid and femoral atherosclerotic plaques [0.03%]
人颈动脉和股动脉粥样硬化斑块洗脱液中促动脉粥样硬化的PAPP-A酶活跃
Mette Faurholdt Gude,Rikke Hjortebjerg,Mette Bjerre et al.
Mette Faurholdt Gude et al.
Background: Pregnancy-associated plasma protein-A (PAPP-A) regulates bioavailability of insulin-like growth factor 1 (IGF1) in various tissues by proteolytic cleavage of a subset of IGF-binding proteins (IGFBPs). Pre-clin...
Extreme founder effect associated with hyperglycemia and hyperlipidemia on the island of NIAS/Indonesia [0.03%]
尼西亚岛/印度尼西亚极端奠基者效应与高血糖和高脂血症的相关性研究
Ingo Kennerknecht,Johannes M Hämmerle,Manfred Fobker et al.
Ingo Kennerknecht et al.
The island of Nias/Indonesia shows an extremely reduced genetic diversity indicating a strong founder effect. As a consequence, the prevalence of some disease genes should significantly differ among populations depending on the gene pool pa...
Associations of very low Lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver disease [0.03%]
极低脂蛋白(a)水平与新发糖尿病和非酒精性肝病风险的关系
Ming Wai Yeung,M Abdullah Said,Yordi J van de Vegte et al.
Ming Wai Yeung et al.
Background and aims: We aimed to study the association of very low serum Lipoprotein(a) [Lp(a)] concentrations with new-onset type 2 diabetes (T2D) and non-alcoholic liver disease (NAFLD) in the context of statin usage in...
Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinic [0.03%]
在专门的脂质诊所随访的遗传学确诊家族性高胆固醇血症儿童和青少年中的Lp(a)
Anja K Johansen,Martin P Bogsrud,Magne Thoresen et al.
Anja K Johansen et al.
Background and aim: Many children with an FH mutation also exhibit elevated lipoprotein(a) levels, which is an independent risk factor for atherosclerotic cardiovascular disease. Studies have reported higher levels of lip...
Chongxu Shi,Zhaozhi Wen,Yihang Yang et al.
Chongxu Shi et al.
Nicotinamide adenine dinucleotide (NAD+) is a central and pleiotropic metabolite involved in cellular energy metabolism, cell signaling, DNA repair, and protein modifications. Cardiovascular diseases (CVDs) are the leading cause of death wo...
Trends in cardiovascular disease among Inuit in Greenland from 1994 to 2021 [0.03%]
1994年至2021年格陵兰因纽特人心血管疾病流行趋势
Hjalte Erichsen Larsen,Uka Wilhjelm Geisler,Finn Gustafsson et al.
Hjalte Erichsen Larsen et al.
Background and aims: Cardiovascular disease (CVD) poses significant health challenges globally. While substantial data exists for most populations, the Arctic Inuit's CVD incidence rates remain understudied. This research...
Carotid intima-medial thickness in patients with severe hypertriglyceridemia [0.03%]
严重高甘油三酯血症患者的颈动脉中膜厚度变化
Maud Ahmad,Brooke A Kennedy,Surim Son et al.
Maud Ahmad et al.
Background and aims: Severe hypertriglyceridemia (HTG), defined as plasma triglyceride (TG) concentration > 10 mmol/L, is relatively uncommon, and its implications for atherosclerotic cardiovascular disease (ASCVD) risk r...
Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial [0.03%]
利拉鲁肽与他汀治疗的2型糖尿病冠心病患者冠状动脉斑块脱脂：OPTIMAL随机临床试验的预设子分析研究
Yu Kataoka,Satoshi Kitahara,Sayaka Funabashi et al.
Yu Kataoka et al.
Background and aims: Randomized clinical trials have demonstrated the ability of glucagon-like peptide-1 analogues (GLP-1RAs) to reduce atherosclerotic cardiovascular disease events in patients with type 2 diabetes (T2D)....
Treatment intensification with bempedoic acid to achieve LDL-C goal in patients with ASCVD: A simulation model using a real-world patient cohort in the US [0.03%]
在ASCVD患者中使用贝梅普 Dor 酸强化治疗以达到LDL-C目标：基于美国真实世界患者队列的模拟模型
Kristen Migliaccio-Walle,David Elsea,Anand Gupta et al.
Kristen Migliaccio-Walle et al.
Background and aims: Guidelines recommend that high-risk patients with atherosclerotic cardiovascular disease (ASCVD) be treated with maximally tolerated statins to lower low-density lipoprotein cholesterol (LDL-C) levels...
The effect of hydroxychloroquine on cholesterol synthesis depends on the profile of cholesterol metabolism. A controlled clinical study [0.03%]
羟氯喹对胆固醇合成的影响取决于胆固醇代谢的特性。一项控制临床研究
Piia Simonen,Lotta Ulander,Kari K Eklund et al.
Piia Simonen et al.
Background and aims: Hydroxychloroquine (HCQ) has a variable effect on cholesterol synthesis. To clarify this, we assessed the effect of HCQ on the cholesterol-synthesis pathway in individuals with low and high cholestero...